PHARMEXCIL Strengthens India-UAE Partnership

Hyderabad:  The Pharmaceutical Export Promotion Council of India (PHARMEXCIL) has announced its renewed commitment to strengthening the strategic partnership between India and the United Arab Emirates (UAE) in the pharmaceutical sector.

Raja Bhanu, Director General of PHARMEXCIL along with the Advisor to Pharmexcil AVPS Chakravarthi recently had the privilege of meeting Aref Ali Alnuaimi, Consul General of the UAE, in Hyderabad. The meeting highlighted the enduring economic and commercial ties between the two nations, with a particular focus on pharmaceutical exports and collaboration in drug development, formulations, vaccines, and Active Pharmaceutical Ingredients (APIs).

As part of its efforts to enhance this collaboration, PHARMEXCIL is hosting the India Pavilion at Arab Health 2025, one of the most prestigious healthcare and pharmaceutical exhibitions in the region. Scheduled to take place from January 27-30, 2025, at the World Trade Center (WTC), Dubai to be inaugurated by Satish Kumar Siven, Consul General of India to UAE at Dubai on 27th January, 2025 This premier event will feature participation from 65 leading Indian pharmaceutical companies.

The India Pavilion will serve as a showcase for India’s excellence in pharmaceutical manufacturing and innovation, offering a platform for Indian companies to present their products and capabilities to global stakeholders, explore new business opportunities, and deepen engagement with the UAE market.

PHARMEXCIL invites stakeholders from across the healthcare industry to visit the India Pavilion and explore the vast potential of Indian pharmaceuticals.

SOURCE : BioSpectrum India

Related Posts

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

New Delhi: Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research and development activities with the business representatives of the pharmaceutical industry. “Had…

Senores Pharma to Buy Two Teva ANDAs

Mumbai, August 14, 2025 — Senores Pharmaceuticals will acquire two abbreviated new drug applications (ANDAs) from Teva Pharmaceuticals USA. The deal is Senores’ third US move in six months, underscoring…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

Senores Pharma to Buy Two Teva ANDAs

Senores Pharma to Buy Two Teva ANDAs

Lab-grown rabies antibodies show promise as cheaper, safer alternative

Lab-grown rabies antibodies show promise as cheaper, safer alternative

Lilly launches Mounjaro KwikPen in India

Lilly launches Mounjaro KwikPen in India